Abstract
Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to metastatic disease. The progression of CaP from primary to metastatic disease is associated with a number of molecular and genetic changes. These changes can effect the expression of specific tumor-associated antigens (TAAs) or receptors on the cell surface. Current therapeutic options for patients with metastatic hormone-refractory CaP (HRPC) are very limited. Targeting cancer surface TAAs is a developing area, and may have a promising future for control of late stage and recurrent CaP disease. This review describes some important CaP TAAs including prostate-specific membrane antigen (PSMA), MUC1, urokinase plasminogen activator and its receptor (uPA/uPAR), vascular endothelial growth factor and its receptor (VEGF/VEGFR), extracellular matrix metalloproteinase inducer (EMMPRIN/CD147), epidermal growth factor receptor (EGFR), platelet-derived growth factor and its receptor (PDGF/PDGFR) and c-kit (CD117). We summarize recent progress supporting the role of these TAAs in CaP progression and establish the potential therapeutic efficacy of TAAstargeted therapies in CaP.
Keywords: Cancer therapy, prostate cancer, tumor-associated antigen, metastasis
Current Cancer Therapy Reviews
Title: Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy
Volume: 4 Issue: 4
Author(s): Paul J. Cozzi, John Kearsley and Yong Li
Affiliation:
Keywords: Cancer therapy, prostate cancer, tumor-associated antigen, metastasis
Abstract: Prostate cancer (CaP) is one of the most common malignancies in men, with an increasing incidence. Despite advances in surgery, chemotherapy and radiotherapy to treat CaP, many patients unfortunately succumb to metastatic disease. The progression of CaP from primary to metastatic disease is associated with a number of molecular and genetic changes. These changes can effect the expression of specific tumor-associated antigens (TAAs) or receptors on the cell surface. Current therapeutic options for patients with metastatic hormone-refractory CaP (HRPC) are very limited. Targeting cancer surface TAAs is a developing area, and may have a promising future for control of late stage and recurrent CaP disease. This review describes some important CaP TAAs including prostate-specific membrane antigen (PSMA), MUC1, urokinase plasminogen activator and its receptor (uPA/uPAR), vascular endothelial growth factor and its receptor (VEGF/VEGFR), extracellular matrix metalloproteinase inducer (EMMPRIN/CD147), epidermal growth factor receptor (EGFR), platelet-derived growth factor and its receptor (PDGF/PDGFR) and c-kit (CD117). We summarize recent progress supporting the role of these TAAs in CaP progression and establish the potential therapeutic efficacy of TAAstargeted therapies in CaP.
Export Options
About this article
Cite this article as:
Cozzi J. Paul, Kearsley John and Li Yong, Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy, Current Cancer Therapy Reviews 2008; 4 (4) . https://dx.doi.org/10.2174/157339408786413371
DOI https://dx.doi.org/10.2174/157339408786413371 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism Advancement of Traditional Chinese Medicine in Regulation of Intestinal Flora: Mechanism-based Role in Disease Management
Recent Patents on Anti-Cancer Drug Discovery New Tubulin Polymerization Inhibitor Derived from Thalidomide: Implications for Anti-Myeloma Therapy
Current Medicinal Chemistry Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Phosphine-Gold(I) Compounds as Anticancer Agents: General Description and Mechanisms of Action
Anti-Cancer Agents in Medicinal Chemistry New Therapeutic Strategy for Parkinson’s and Alzheimer’s Disease
Current Medicinal Chemistry Current Advances in Antibody Immobilization on Different Surfaces and Beads
Current Proteomics Nanotechnology Versus other Techniques in Improving Drug Dissolution
Current Pharmaceutical Design Epigenetic Effects of Environmental Chemicals on Reproductive Biology
Current Drug Targets Microbubble-Assisted p53, RB, and p130 Gene Transfer in Combination with Radiation Therapy in Prostate Cancer
Current Gene Therapy Nitric Oxide, Epileptic Seizures, and Action of Antiepileptic Drugs
CNS & Neurological Disorders - Drug Targets The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Regulatory Aspects of Oncolytic Virus Products
Current Cancer Drug Targets Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives
Current Bionanotechnology (Discontinued) The Effects of the Endocrine Disruptors Dithiocarbamates on the Mammalian Ovary with Particular Regard to Mancozeb
Current Pharmaceutical Design